Wells Fargo lowered the firm’s price target on Zimmer Biomet to $119 from $152 and keeps an Equal Weight rating on the shares. The firm notes Q3 sales were roughly in line, but EPS was ahead. 2023 sales and EPS guidance was also maintained, Wells adds.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ZBH: